Affiliation:
1. Department of Biotechnology , School of Engineering & Technology (SET) , Sharda University , Greater Noida , Uttar Pradesh , India
Abstract
Abstract
Protein therapeutics are in great demand due to their effectiveness towards hard-to-treat diseases. Despite their high demand, these bio-therapeutics are very susceptible to degradation via aggregation, fragmentation, oxidation, and reduction, all of which are very likely to affect the quality and efficacy of the product. Mechanisms and modelling of these degradation (aggregation and fragmentation) pathways is critical for gaining a deeper understanding of stability of these products. This review aims to provide a summary of major developments that have occurred towards unravelling the mechanisms of size-based protein degradation (particularly aggregation and fragmentation), modelling of these size-based degradation pathways, and their control. Major caveats that remain in our understanding and control of size-based protein degradation have also been presented and discussed.
Subject
Cellular and Molecular Neuroscience,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference121 articles.
1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14.
2. Otvos L Jr, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014 Aug;2:62–72.
3. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014 Apr–Jun;11(2):99–109.
4. Rathore AS, Joshi V, Yadav N. Aggregation of monoclonal antibody products: formation and removal. Biopharm Int. 2013;26(3):40–5.
5. Arora I, Bansal R, Joshi V, Rathore AS. Aggregation Kinetics for Monoclonal Antibody Products. Int J Chem Eng Appl. 2014;5(5):433–8.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献